First, rivastigmine has a selective effect on G1 enzymatic isoform of acetylcholinesterase, that predominates in patients with AD [23]; second, rivastigmine inhibits not only acetylcholinesterase but also butyrylcholinesterase that is able of compensating for acetylcholinesterase function in case of deficiency [24]; third, the low protein binding property of rivastigmine is indicative of reduced drug interactions [23] and higher compliance, especially in elderly AD patients who typically have concomitant illnesses and take multiple medications [25]. The gene discussed is ACHE; the disease is Alzheimer disease.